ABSTRACT

Objective: To determine prevalence of adverse drug events (ADEs) in patients aged 45 years or older presenting to Australian general practitioners (GPs) and identify drug groups related to ADEs, their severity and manifestation.

Design: Substudy of the Bettering the Evaluation and Care of Health continuous survey of Australian GP clinical activity in which randomly selected GPs collected survey data from patients. Data are reported with 95% CIs.

Setting: General practice in Australia.

Main outcome measures: Prevalence in the preceding 6 months, type, implicated drugs, severity (including hospitalisation) and manifestation of ADEs.

Participants: From three survey samples, January–October 2007, and two samples, January–March 2010, responses were received from 482 GPs about 7561 patients aged 45 years or older.

Results: Of a final sample of 7518 patients (after duplicate patients removed), 871 (11.6%) reported ADEs in the previous 6 months. The type of ADE was recognised side effect (75.8%, 95% CI 72.0 to 79.7), drug sensitivity (9.9%, 95% CI 7.2 to 12.7) and drug allergy (7.4%, 95% CI 4.7 to 10.1). Drug interaction (1.0%, 95% CI 0.1 to 1.8), overdose (0.8%, 95% CI 0.0 to 1.5) and contraindications (0.2%, 95% CI 0.0 to 0.6) were very infrequent. A severity rating was provided for 846 patients. Almost half (45.9%, 95% CI 42.0 to 49.7) were rated as ‘mild’ events, 42.2% (95% CI 38.8 to 45.6) ‘moderate’, 11.8% (95% CI 9.5 to 14.1) severe and 5.4% (95% CI 3.8 to 7.0) had been hospitalised as a result of the most recent ADE. Thirteen commonly prescribed drug groups accounted for 58% of all ADEs, opioids being the group most often implicated.

Conclusion: ADEs in patients aged 45 or older are frequent and are associated with significant morbidity. Most of ADEs result from commonly prescribed drugs at therapeutic dosage. The list of causative agents bears little relationship to published lists of ‘inappropriate medications’.

INTRODUCTION

The Australian healthcare system is similar in many ways to most others in the Organisation for Economic Co-operation and Development (OECD) group of nations. In 2011, Australia had a population of 22.5 million people, cared for by 22 500 primary medical care practitioners who are the gatekeepers to the secondary and tertiary health sectors. There is a universal medical insurance scheme (Medicare) administered by the Australian Government. Primary medical care is provided on a fee-for-service basis without patient enrolment lists. In 2011, there were about 120 million claims for primary medical care services per year at an average of five services per head of population.5

In common with other OECD countries, Australia has an ageing population with a resulting increase in the prevalence of multimorbidity2 3 and polypharmacy. Polypharmacy in older patients is accompanied by a high level of adverse drug events (ADEs).4-7 Miller et al6 found that 15% of patients aged 65 years and older in Australia reported an ADE in the 6 months prior to their surveyed attendance at a primary medical care encounter. The significant morbidity from ADEs in older patients has been widely reported in the literature.6 7 9

Worldwide concern regarding ADEs in older patients has led to attempts to identify ‘inappropriate medications’ (IMs) that may be causing ADEs in order to guide prescribing and reduce patient risk. In 1991, Beers et al10 defined explicit criteria for determining
inappropriate medication use in the elderly using a consensus (Delphi) process. The Beers list was revised in 1997\(^1\) and by Fick \textit{et al.}\(^2\) in 2003.

Laroche \textit{et al.} reviewed the correlation between the use of IMs as defined by Beers \textit{et al.} and others and the occurrence of ADEs in multiple studies and concluded that ‘more than the inappropriateness of the drugs themselves, it is the inappropriate use of drugs that is to be tackled when treating the elderly’. Laroche \textit{et al.}\(^2\) also suggested that the reduction in the number of drugs given is the major factor in the prevention of ADEs. However, little data are available on which drugs used by older patients in community practice are significantly associated with ADEs and are thus the drugs to be considered in any recommendations to reduce use.

The aim of this study was to identify the drug groups related to the occurrence and severity of ADEs in community patients aged 45 and older and the manifestations of these ADEs.

\section*{METHODS}

\subsection*{Collection methods and sample}

This study was conducted through the Bettering the Evaluation and Care of Health (BEACH) program. BEACH is a continuous, national, cross-sectional survey of Australian general practice activity. The BEACH methods are described in detail elsewhere,\(^{13}\) but in summary, general practitioners (GPs) from ever-changing random samples of the (approximately) 18,000 currently practising recognised GPs in Australia are invited to participate. Annually, 1,250 GPs are recruited and posted survey packs, from which approximately 1,000 completed surveys are returned. Each GP records details for 100 consecutive encounters with consenting, unidentified patients, on structured paper forms. Information is collected about the problems managed and how they are managed, for each patient at the single visit on the day the GP is participating.\(^{13}\)

Because the survey is cross-sectional, patients may have health problems that were not managed at the recorded visit. To investigate these aspects of the patient health, a series of substudies are conducted in conjunction with the ongoing data collection from the GP–patient encounters. In each 5 week collection period about 100 GPs each records information for approximately 30 consecutive patients for each topic, a completed sample of about 3,000 patients per substudy.\(^{14}\) These substudies, known as Supplementary Analysis of Nominated Data (SAND), investigate aspects of the patient health not necessarily managed at the encounter (full methods reported elsewhere).\(^{15}\) Responses are recorded by the GP about the patient, in discussion with the patient. Using a qualified medical practitioner to record morbidity in conjunction with the patient self-report may provide a more accurate classification of patients’ health problems than the self-report alone.\(^{16,17}\) A total of five SAND subsamples were used: three data collection periods were between January and October 2007; and two between January and March 2010. These data were used to investigate the frequency, cause, reaction type (recognised side effect, drug interaction, contraindication, allergy, drug sensitivity, overdose or other) and severity of ADEs reported by patients to have occurred within the previous 6 months.

\subsection*{Adverse drug events}

For the purpose of this study, an ADE is defined as an ‘intended event, due to the use of a medication that could have harmed or did harm the patient’. ‘Harm’ includes physical, psychological or emotional suffering. This definition is consistent with the definition of the broader concept of ‘clinical incidents’ used in our seminal work on the patient safety incidents in general practice in Australia.\(^18\)

\subsection*{Data collected}

The number of questions that could be asked about the patient was limited by the space available on the recording form. Each GP was asked to record whether or not each of the 30 patients had experienced an ADE in the preceding 6 months. If the response was ‘no’ the questions ended. Where a ‘yes’ response was recorded, the GP was then asked to report on the medication or medications involved in the most recent event. The GP was then asked to record the type of adverse event. Nine options with tick boxes were offered for recording the type of the event: a recognised side effect, drug interaction, contraindication, allergy, drug sensitivity, overdose, dispensing error, don’t know and other. Type was not recorded in the last two collection periods. Severity was recorded as one of four options (mild, moderate, severe and don’t know). Hospitalisation was recorded for all patients with ADEs. GPs were asked to use their clinical judgement in assessing the severity of the ADE but guiding definitions were provided (box 1).

In the two collection periods in 2010 the GPs were also asked to record the symptoms and signs resulting from the ADE, and their duration.

There were no statistical differences in the age and sex distributions of respondents between the collection periods and between the collections and the whole BEACH collection during the same period (results not tabled). For subsequent analysis of ADE prevalence,
causative drug, severity and hospitalisation, all five samples were amalgamated into a single sample.

As the age group of interest for this paper was older Australians, who have significantly higher rates of ADEs than younger Australians, and as there was no statistical difference between the ADE rates for all age groups 45 years and above (figure 1), patients in these age groups were amalgamated for analysis.

Classification of data
Drugs reported as implicated in the cause of ADEs were classified using the WHO’s Anatomical Therapeutic Chemical (ATC) classification. Manifestations of the ADEs were classified according to the International Classification of Primary Care V.2 (ICPC-2).

Comparison of rates of prescribing and ADEs
We compared prescribing rates (drug group as a proportion of all drugs prescribed) derived from BEACH data for the years 2007–10, with ADE rates (drug group as a proportion of all ADEs) for groups of drugs at ATC classification level 3. If each drug group had an equal likelihood of producing ADEs, the rate of ADEs produced by a drug group should be similar to the rate of prescribing. We used non-overlapping CIs as a conservative measure of the likelihood that one drug group was more or less likely to result in ADEs than another.

Statistical analysis
A cluster sample design was used with the GP being the primary sampling unit, and the patient at the encounter the unit of analysis. Procedures in SAS V.9.1.21 accounting for the cluster study design were used to determine robust 95% CIs for the resulting estimates and percentages. Significance of differences was judged by non-overlapping CIs. Where responses were not provided, missing data were removed from the analyses.

An unadjusted prevalence estimate was calculated as the number of patients with at least one ADE as a proportion of the total sample of respondents. This estimate can be interpreted as the prevalence of ADEs among patients who present to GPs.

RESULTS
Response rates
The responses received on 7561 encounter forms from patients aged 45 years or over, were provided by 482 GPs. Of these, 35 were excluded, (duplicate patients on the basis of matching demographic data), leaving a final sample of 7518 patients. The age and sex distributions of the respondents did not differ from those of patients in the total sample of BEACH encounters for 2006–2010.

Rates of ADEs
The GPs reported that 871 patients aged 45 or older (11.6%) had experienced an adverse event in response to using a medication in the previous 6 months. This result was consistent over the five recording periods (table 1). All other results from questions repeated in the five recording blocks did not significantly differ and are reported here in consolidated form.

Our previously published research demonstrated that the likelihood of an ADE increased with age to peak in those aged 45–64 years and remained at the same level in those in older age groups. This distribution of ADEs with age was confirmed in this study (figure 1). Women (12.9%, 95% CI 11.6 to 14.2) were significantly more likely than male patients (9.5%, 95% CI 8.3 to 10.7) to have experienced an ADE.

For the vast majority (91.7%) of 842 respondents only one drug was said to be implicated in the most recent ADE, but in 8.3% two drugs were implicated.

Type of ADEs
Type of the ADEs was investigated in the first three collection periods. Of the 533 patients in these collection periods, GPs reported type of ADEs for 525 patients. The GPs assessment of the type of the ADE was: recognised side effect for 75.8% (95% CI 72.0 to 79.7) of occurrences, drug sensitivity for 9.9% (95% CI 7.2 to 12.7) and drug allergy for 7.4% (95% CI 4.7 to 10.1). Prescribing errors such as drug interaction (1.0%, 95% CI 0.1 to 1.8), overdose (0.8%, 95% CI 0.0 to 1.5) and contraindications (0.2%, 95% CI 0.0 to 0.6) were very infrequent.

Severity of ADEs
A GP severity rating for the most recent ADE was provided for 846 patients. Almost half (45.9%, 95% CI 42.0 to 49.7) were rated as having a ‘mild’ event(s), with 42.2% (95% CI 38.8 to 45.6) rated as ‘moderate’. A ‘severe’ rating was given for 100 patients, 11.8% (95% CI 9.5 to 14.1) of those with an ADE for whom a response to this question was received.

Hospitalisation for ADEs
Responses to the question on hospitalisation were received for 831 patients, of whom 5.4% (95% CI 3.8 to 7.0) had been hospitalised as a result of the most recent ADE. Hospitalisation rates were highest in those

Figure 1 Age-specific rate of adverse drug events (ADE)
patients whose ADE was rated as severe (31.6%, 95% CI 22.3–1.0).

**Medications associated with ADEs**

Table 2 shows the 13 drug groups (ATC level 3) most frequently implicated in ADEs in this study in ADE frequency order. Together these drug groups accounted for 58.6% of all reported ADEs. The relative prescribing frequency and relative ADE frequency for each group are also provided. Also shown are the most commonly implicated drug subgroups (at ATC level 4 or at level 3 in some instances where the whole group is implicated) with the distribution of grades of severity of ADEs and frequency of hospitalisation. The last column shows the most common manifestations of the ADEs for each drug subgroup.

Opioids were the most frequently implicated drugs, accounting for 8.2% of all ADEs, with natural opium alkaloids (4.2% of ADEs) the most common subgroup. While 52.8% of ADEs caused by natural opium alkaloids were mild, 16.7% were rated severe and 19.4% resulted in hospitalisation. These accounted for 14.3% of all hospitalisation for ADEs in this study. The recorded manifestations were those which would be clinically expected from this group of drugs.

ADEs from salicylates and non-steroidal anti-inflammatory drugs (NSAIDs) were also relatively frequent causes of hospitalisation and together accounted for 12.2% of all hospitalisations for ADEs in this study.

When the relative prescribing and ADE rates were considered it was apparent that NSAIDs, antidepressants and bone mineralisation drugs had rates of ADEs that were significantly higher than the relative prescribing rates, while for drugs for peptic ulcer and gastro-oesophageal reflux disease (including proton pump inhibitors and histamine 2 receptor antagonists), the ADE rate was significantly less than the relative prescribing rate.

**DISCUSSION**

More than 1 in 10 patients aged 45 and over presenting to a GP in Australia have experienced an ADE in the preceding 6 months, 54% being in the moderate to severe range of GP assessed severity and 5.4% being hospitalised as a result of the ADE.

This study is limited by the methodology of the SAND substudies of the BEACH programme, being constrained by the number of questions that could be asked and by the time that the GP could devote to clarifying the answers within the context of the consultation.

Patients attend general practice at variable rates related to age and morbidity. Therefore, some groups of patients are more likely to be included in these samples. As a result, the frequency of ADEs in patients attending GPs cannot be extrapolated to period prevalence of ADEs in the community.

The questions relied on patient/GP recall of events in the previous 6 months, so there may be some recall bias.
<table>
<thead>
<tr>
<th>Drug group</th>
<th>BEACH (2007–2010) Relative prescribing frequency, per cent (95% CI; n=170 492)</th>
<th>SAND (all samples) Relative ADE frequency, per cent (95% CI; n=912)</th>
<th>Drug sub-group, ATC level 4 or ATC level 3 (ATC code) Relative ADE frequency, per cent (95% CI; n=912)</th>
<th>Severity of ADE</th>
<th>Hospitalised</th>
<th>SAND (2010 samples only) Manifestation of most recent ADE Main type/s of reaction (ICPC-2 rubrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opioids</td>
<td>ATC code: N02A 6.5 (6.3 to 6.7)</td>
<td>Natural opium alkaloids (N02AA) 4.2 (2.7 to 5.6)</td>
<td>52.8 30.6 16.7</td>
<td>Mild, percentage of subgroup</td>
<td>19.4 14.3</td>
<td>Constipation, vomiting, nausea, vertigo/dizziness and sleep disturbance</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>ATC code: N06A 4.3 (4.1 to 4.4)</td>
<td>Selective serotonin reuptake inhibitors (N06AB) 3.7 (2.7 to 0)</td>
<td>47.1 41.2 11.8</td>
<td>Moderate, percentage of subgroup</td>
<td>3.1 2.0</td>
<td>Feeling anxious, diaphoresis and palpitations</td>
</tr>
<tr>
<td>Lipid-modifying agents, plain</td>
<td>ATC code: C10A 6.1 (5.9 to 6.2)</td>
<td>Statins (C10AA) 6.4 (4.5 to 8.2)</td>
<td>36.2 48.3 15.5</td>
<td>Severe, percentage of subgroup</td>
<td>3.4 0.0</td>
<td>Muscle pain, urticaria and digestive symptom NOS</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>ATC code: M01A 3.7 (3.6 to 3.9)</td>
<td>NSAIDs (M01A) 6.3 (4.7 to 7.8)</td>
<td>45.6 45.6 8.8</td>
<td>Percentage of sub-group</td>
<td>10.5 8.1</td>
<td>Abdominal/epigastric pain, nausea and swollen ankles/oedema</td>
</tr>
<tr>
<td>ACE inhibitors, plain</td>
<td>ATC code: C09A 4.0 (3.9 to 4.1)</td>
<td>ACE inhibitors—plain (C09AA) 5.3 (3.7 to 6.8)</td>
<td>64.6 31.3 4.2</td>
<td>Column, per cent</td>
<td>0.0 0.0</td>
<td>Cough</td>
</tr>
<tr>
<td>Penicillins</td>
<td>ATC code: J01C 3.9 (3.7 to 4.0)</td>
<td>Penicillins (J01C) 4.8 (3.4 to 6.3)</td>
<td>50.0 38.6 11.4</td>
<td>Diaphoresis, rash and nausea</td>
<td>4.5 4.1</td>
<td>Swollen ankles/oedema and rash</td>
</tr>
<tr>
<td>Selective calcium channel blockers with mainly vascular effects</td>
<td>ATC code: C08C 2.6 (2.5 to 2.7)</td>
<td>Calcium channel blockers (C08C) 3.9 (2.7 to 5.2)</td>
<td>55.6 30.6 13.9</td>
<td>Other analgesics</td>
<td>0.0 0.0</td>
<td></td>
</tr>
<tr>
<td>Other analgesics</td>
<td>ATC code: N02B 3.3 (3.2 to 3.4)</td>
<td>Salicylates (N02BA) 1.4 (0.7 to 2.2)</td>
<td>46.2 38.5 15.4</td>
<td>Diaphoresis, rash and nausea</td>
<td>16.7 4.1</td>
<td>Cardiac arrhythmia, malaena, haematuria and haemoptysis</td>
</tr>
<tr>
<td>β blocking agents</td>
<td>ATC code: C07A 2.9 (2.8 to 3.0)</td>
<td>Anilides (N02BE) 2.5 (1.4 to 3.6)</td>
<td>52.2 39.1 8.7</td>
<td>Other analgesics</td>
<td>0.0 0.0</td>
<td>Tinnitus</td>
</tr>
<tr>
<td>Hypoglycaemic agents excluding insulins</td>
<td>ATC code: A10B 3.4 (3.3 to 3.5)</td>
<td>Biguanides (A10BA) 1.5 (0.7 to 2.3)</td>
<td>14.3 71.4 14.3</td>
<td>Cardiac arrhythmia, nausea, weakness/tiredness and postural hypotension</td>
<td>7.1 2.0</td>
<td></td>
</tr>
<tr>
<td>Drugs for bone structure and mineralisation</td>
<td>ATC code: M05B 0.9 (0.9 to 1.0)</td>
<td>Bisphosphonates (M05BA/BB) 1.5 (0.7 to 2.3)</td>
<td>38.9 38.9 22.2</td>
<td>Other analgesics</td>
<td>0.0 0.0</td>
<td>Fever, nausea and pain</td>
</tr>
<tr>
<td>Drugs for peptic ulcer and gastro-oesophageal reflux disease</td>
<td>ATC code: A02B 4.4 (4.3 to 4.5)</td>
<td>Proton pump inhibitors (A02BC) 2.0 (1.1 to 2.9)</td>
<td>38.9 44.4 16.7</td>
<td>Other analgesics</td>
<td>6.3 2.0</td>
<td>Diaphoresis and abdominal pain</td>
</tr>
<tr>
<td>Antiepileptics</td>
<td>ATC code: N03A 0.8 (0.7 to 0.8)</td>
<td>Antiepileptics (N03A) 1.8 (0.8 to 2.7)</td>
<td>56.3 31.3 12.5</td>
<td>Other analgesics</td>
<td>6.3 2.0</td>
<td>Neurological symptom NOS, sleep disorder and speech disorder</td>
</tr>
</tbody>
</table>

ADE, adverse drug events; ATC, Anatomical Therapeutic Chemical; BEACH, Bettering the Evaluation And Care of Health; ICPC-2, International Classification of Primary Care Version 2; NOS, not otherwise specified; NSAIDs, Non-Steroidal Anti-Inflammatory Agents; SAND, Supplementary Analysis of Nominated Data.


Open Access

On June 3, 2022 by guest. Protected by copyright.
The study must therefore be regarded as a quantification of ADEs from the perspective of the GP and the patient. The GP was therefore the judge of appropriateness of indication and dosage of drugs causing ADEs and this may introduce a bias against reporting inappropriate indication or dose. However, the overall consistency of the results over five collection periods by different groups of about 100 GPs suggests a common interpretation of causality and severity.

A major strength of this study is that it contains data from a large sample of patients collected by hundreds of randomly selected GPs representing 2.7% of all the practising GPs in Australia. GPs in the BEACH programme are nationally representative of all the GPs practising in Australia.22 The GPs use their medical records, knowledge of the patient and their clinical skills and experience to interpret the reported ADEs. In the SAND substudies they act as expert clinical interviewers.

Research on under-reporting of serious ADEs in the USA23–25 and Canada,26–28 suggests that formal reporting rates may represent as little as 1.5% of total ADEs. USA estimates place the mortality from ADEs as the fifth most common cause of death after heart disease, cancer, stroke and pulmonary disease.25 The level of morbidity revealed in this study must place ADEs as one of the most important causes of morbidity in the Australian community. The most severe result of ADEs, namely death, was of course not included, as this was a study of patients attending a GP. While the very severe ADEs may occur and be managed in the acute care sector, a large number of mild and moderate ADEs and many of the severe reactions must be managed in the community.

While the vast majority of studies in the literature concentrate on prescribing ‘errors’ and ‘preventable’ ADEs, this study and our previous research demonstrates that the large majority of ADEs occurring in primary medical care in Australia fall into the WHO category of adverse drug reactions (ADRs),29 occurring in patients on appropriate dosages of medication, prescribed for appropriate indications. This group of ADEs are frequently ignored as the ‘price we pay’ for effective management of disease. However, there is further evidence from this study that for many patients the price may be too high.

The list of drugs implicated in this study as associated with ADEs bears little relationship to lists of ‘IMs’ such as that developed by Beers et al. A large number of ‘appropriate medications’ are implicated as causing ADEs. Gandhi et al.30 in a prospective study of ADEs in primary care in Boston, also found that ADEs are frequently caused by similar commonly used groups of drugs. Budnitz et al.31 studying emergency hospitalisations for ADEs, also concluded “most emergency hospitalisations for recognised ADEs in older adults resulted from a few commonly used medications, and relatively few resulted from medications typically designated as high risk or inappropriate.” Laroche et al also found that ADEs in elderly patients (70 years and older) were rarely caused by IMs.4 Many of the drug groups implicated as causes of ADEs in this study are used for the prevention of cardiovascular disease. These drugs may have little perceived immediate benefit in the eyes of the patients while inducing significant morbidity from ADEs.

Considering the wide range of drugs that cause significant reactions at therapeutic dosage levels, constant vigilance is required by clinicians to minimise the risk of ADEs. Reducing the number of drugs taken by older patients is paramount in efforts to reduce ADRs. Inclusion of information about the frequency and severity of ADEs in prescribing decision support systems may assist GPs to weigh the risk/benefit of commonly used medications in older patients.

**Acknowledgements** The authors would like to thank the GPs who participated, and the Primary and Ambulatory Care Division of the Australian Government Department of Health and Ageing for supply of the BEACH GP sample frame data.

**Contributors** All authors contributed to the conception and design, interpretation of data, drafting and critical revision of important intellectual content. All authors had full access to all the data. LV performed the statistical analysis. GCM wrote the first draft of the article and all authors approved the final version. GCM is the study guarantor.

**Funding** Between 2006 and 2010 the BEACH programme, of which this substudy is a part, was funded by the Australian Government Department of Health and Ageing, the Australian Government Department of Veterans’ Affairs, Australian Institute of Health and Welfare, National Prescribing Service, AstraZeneca Pty Ltd (Australia), Janssen-Cilag Pty Ltd, Merck, Sharp and Dohme (Australia) Pty Ltd, Pfizer Australia Pty Ltd, Abbott Australasia Pty Ltd, Sanofi-Aventis Australia Pty Ltd, Novartis Pharmaceuticals Australia Pty Ltd, GlaxoSmithKline Australia Pty Ltd, Bayer Australia Ltd. The SAND substudy reported in this paper was commissioned by the Family Medicine Research Centre.

**Competing interests** None.

**Ethics approval** The BEACH programme and this substudy were approved by the Human Research Ethics Committee of the University of Sydney (Reference No. 7185) and the Ethics Committee of the Australian Institute of Health and Welfare.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** No additional data are available.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

**REFERENCES**


